ArticleCureus2026
Opposing Ageing-Related Transcriptomic Profiles Distinguish Opioid Exposure Liability From Dependence Liability.
Article in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Opioid use disorder (OUD) involves separable stages of exposure and dependence, but many genetic studies have treated these liabilities as a single phenotype. In this study, transcriptome-wide association study (TWAS) methods were applied to the Psychiatric Genomics Consortium Substance Use Disorders 2020 opioid meta-analysis summary statistics to examine ageing-related gene pathways across brain tissues. Genetic liability for opioid exposure was strongly associated with reduced predicted expression of complement components and synaptic-pruning genes, together with negative signals in astrocyte and senescence-related gene sets. By contrast, liability for dependence among opioid-exposed individuals showed positive enrichment in AMP-activated protein kinase-mechanistic target of rapamycin nutrient-sensing pathways, mitochondrial oxidative phosphorylation, especially DLD, and selected nicotinamide adenine dinucleotide/sirtuin pathways, accompanied by presynaptic and DNA repair-associated signals. Many ageing-related gene sets showed opposing directional profiles between exposure and dependence contrasts, indicating that these stages are associated with partially antagonistic transcriptomic profiles. Gene-level analyses identified influential drivers and directional sign-flips, including CASP7, TERF2, STX1A, and ADCY6, which further supported the stage-specific pattern. A dedicated post-hoc robustness inventory was performed, including threshold variation, family-wise false discovery rate pooling, tissue-specific decomposition, gene-set overlap analysis, major histocompatibility complex/complement flagging, and leave-one-out influence analysis. In this inventory, 131 of 4913 pooled statistical tests survived global Benjamini-Hochberg false discovery rate correction, and 100 of 102 evaluable pathway-profile entries satisfied an opposing exposure-versus-dependence criterion. These findings suggest that opioid exposure and opioid dependence are biologically distinguishable at the level of ageing-related brain gene expression. The results nominate stage-specific risk modules and biomarker hypotheses that may inform future precision approaches to OUD prevention and treatment while remaining hypothesis-generating until validated in functional and longitudinal studies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.